No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
FULC240621P7000
- 0.55
- +0.15+37.50%
15min DelayClose Jun 20 16:00 ET
0.70High0.55Low
0.70Open0.40Pre Close2.50K Volume5.02K Open Interest7.00Strike Price145.40KTurnover0.00%IV-1.10%PremiumJun 21, 2024Expiry Date0.62Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma11.60Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Express News | Fulcrum Therapeutics Inc - Increased Size of Board From Eight to Nine Members
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the "Company") (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to imp
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Fulcrum Therapeutics to Participate in the Goldman Sachs' 45th Annual Global Healthcare Conference
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
Goldman Sachs Predicts up to 108% Rally for These 2 'Strong Buy' Stocks
Fulcrum Therapeutics (NASDAQ:FULC) Readies Phase 3 Candidate With Blockbuster Potential
Comments
$Fulcrum Therapeutics(FULC.US$ Its lead candidate, Losmapimod, is a selective p38α/β mitogen-activated protein kinase inhibitor. It is a potentially transformative treatment for FSHD, a rare and debilitating disease for which no approved treatments exist. The FDA has since granted Losmapimod Fast Track designation and Orphan Drug Designation for treating this condition. It is undergoing a Phase 3 study, and Fulcrum expects to report topline data in the fourth quarter of 2024.
1
2
$Fulcrum Therapeutics(FULC.US$ Oh come on what are you waiting for we all know we goin up
$Fulcrum Therapeutics(FULC.US$ Long term looking for dollar 15 range, possible 17 price target to hit. 13.7 resistance 10.4 Fulcrum
5
$Fulcrum Therapeutics(FULC.US$ Fulcrum Therapeutics Inc: Fulcrum Will Receive an Upfront Payment of $80.0 Mln
1
4
Read more
JESSE JAMES8832 : might be something
TrytosaveabitOP JESSE JAMES8832: Yup! I will be looking to see where it starts to consolidate over the next couple weeks. Then start scaling in!